Addex Therapeutics Ltd. (ADXN)

Market Cap	7.31M
Revenue (ttm)	1.58M
Net Income (ttm)	-22.18M
Shares Out	9.14M
EPS (ttm)	-3.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,025
Open	0.820
Previous Close	0.800
Day's Range	0.775 - 0.820
52-Week Range	0.680 - 9.397
Beta	1.76
Analysts	Sell
Price Target	0.87 (+8.8%)
Earnings Date	Aug 18, 2022

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col...

• Industry: Biotechnology
• Founded: 2002
• CEO: Tim Dyer
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: ADXN

Full Company Profile

Financial Performance

In 2021, ADXN's revenue was 2.92 million, a decrease of -19.28% compared to the previous year's 3.61 million. Losses were -15.35 million, 19.4% more than in 2020.

Financial numbers in CHF Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ADXN stock is "Sell." The 12-month stock price forecast is 0.87, which is an increase of 8.78% from the latest price.

Price Target

$0.87

(8.78% upside)

Analyst Consensus: Sell

Stock Forecasts